Plasma Levels of Growth Arrest Specific Protein (Gas6) and the Soluble Form of Its Tyrosine Kinase Receptor Axl (sAxl) in Patients with Hepatocellular Carcinoma

Soichiro Uehara, Katsuhiro Gotoh, Hiroshi Handa, Yoshiyuki Maki

Department of Internal Medicine and Gastroenterology, Hizirigaoka Hospital, Hunaoka, Japan.
Primary Cell Co. Ltd., Sapporo, Japan..

DOI: 10.4236/jct.2013.42079                

Abstract

The aim of this study was to determine the plasma levels of vitamin K-dependent protein growth arrest-specific protein 6 (Gas6) and its soluble receptor Axl (sAxl) in patients with hepatocellular carcinoma (HCC), acute hepatitis (AH), fulminant hepatitis(FH), chronic hepatitis (CH), and liver cirrhosis (LC) and to determine whether Gas6 and sAxl can be used as biomarkers. Immunoassys were used to measure levels of plasma Gas6 and sAxl in 40 patients with HCC, 13 patients with AH, 3 patients with FH, 7 patients with LC, and 20 healthy normal adult controls (NC). Furthermore, urinary γ-carboxyglutamic acid (Gla) was measured by high performance liquid chromatography. We have addressed this issue by conducting a cross-sectional study to determine whether plasma Gas6 and sAxl levels are associated with DCP, urinary γ-Gla, and liver functions in humans. Levels of Gas6, sAxl, and γ-Gla were significantly higher in HCC as compared to those in NC, and they were significantly positive correlated. Gas6/sAxl molar ratios in HCC were significantly higher than in NC, but those ratios in AH, FH, and LC were significantly lower in NC. Furthermore, Gas6/sAxl molar ratios in HCC increased significantly in comparison with those AH and LC. The increase of Gas6, sAxl and Gas6/sAxl molar ratio were correlated with the progression and poor prognosis of HCC. Thus, Gas6 and sAxl may be useful biomarkers for HCC.

Keywords

Gas6; Soluble Axl (sAxl); Receptor Tyrosine Kinase; γ-Carboxyglutamic Acid (γ-Gla); Vitamin K; Hepatocellular Carcinoma (HCC)

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	G. Manfioletti, C. Brancolini, G. Avnzi and C. Schneider, “The Protein Encoded by a Growth Arrest-Specific Gene (gas6) Is a New Member of the Vitamin K-Dependent Proteins Related to Protein S, a Negative Coregulator in the Blood Coagulation Cascade,” Molecular and Cellular Biology, Vol. 13, No. 8, 1993, pp. 4976-4958.
[2]	K. Nagata, K. Ohash, T. Nakano, et al., “Identification of the Product of Growth Arrest-Specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases,” The Journal of Biological Chemistry, Vol. 271, 1996, pp. 3022-3027. Hdoi:10.1074/jbc.271.47.30022
[3]	P. Marcandalli, M. Gostissa, B. Varnum, S. Goruppi and C. Schneider, “Identification and Tissue Expression of Splice Variant for the Growth Aresst-Specific Gene Gas6,” FEBS Letters, Vol. 415, No. 1, 1997, pp. 56-58. Hdoi:10.1016/S0014-5793(97)01094-6
[4]	I. Hasanbasic, J. Cuerquis, B. Varnum and D. M. Blostein, “Intercellular Signaling Pathways Involved in Gas6-AxlMediated Survival of Endothelial Cells,” American Journal of Physiology—Heart and Circulatory Physiology, Vol. 287, No. 3, 2004, pp. H1207-1213.
[5]	R. M. Linger, A. K. Keating, H. S. Earp and D. K. Graham, “TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling and Potential Therapeutic Targeting in Human Cancer,” Advances in Cancer Research, Vol. 100, 2008, pp. 35-83.
[6]	M. Hutterer, P. Knyazev, A. Abate, et al., “Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme,” Clinical Cancer Research, Vol. 14, No. 1, 2008, pp. 130-138.
[7]	A. Gustafsson, D. Martuszewska, M. Johansson, et al., “Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival,” Clinical Cancer Research, Vol. 15, No. 14, 2009, pp. 4742-4749.
[8]	A. P. Tsou, K. M. Wu, T. Y. Tsen, et al., “Parallel Hybridization Analysis of Multiple Protein Kinase Genes: Identification of Gene Expression Patterns Characteristic of Human Hepatocellular Carcinoma,” Genomics, Vol. 50, No. 3, 2010, pp. 331-340.
[9]	L. He, J. Zhang, L. Jiang, et al., “Differential Expression of Axl in Hepatocellular Carcinoma and Correlation with Tumor Lymphatic Metastasis,” Molecular Carcinogenesis, Vol. 49, No. 10, 2010, pp. 882-891. Hdoi:10.1002/mc.20664
[10]	V. Budagian, E. Bulanova, Z. Orinska, et al., “Soluble Axl Is Generated by ADAM10-Dependent Cleavage and Associates with Gas6 in Mouse Serum,” Molecular and Cellular Biology, Vol. 25, No. 21, 2005, pp. 9324-9339. Hdoi:10.1128/MCB.25.21.9324-9339.2005
[11]	B. Furie, B. A. Bouchard and B. C. Furie, “Vitamin K-Dependent Biosynthesis of Gamma-Carboxyglutamic Acid,” Blood, Vol. 93, No. 6, 1999, pp. 1798-1808.
[12]	Y. Inagaki, W. Tang, H. Xu, et al., “Des-γ-Carboxyprothrombin: Clinical Effectiveness and Biochemical Importance,” BioScience Trends, Vol. 2, No. 2, 2008, pp. 53-60.
[13]	P. Yue, Z. H. Gao, X. Xue, et al., “Des-Ganmma-Carboxy Prothrombin Induces Matrix Metalloproteinase Activity in Hepatocellular Carcinoma Cells by Involving the ERK1/2 MARPK Signaling Pathway,” European Journal of Cancer, Vol. 47, No. 7, 2011, pp. 1115-1124. Hdoi:10.1016/j.e jca.2011.01.017
[14]	N. Hotta, M. Avada, K. Sato, et al., “Effect of Vitamin K2 on the Recurrence in Patients with Hepatocellular Carcinoma,” Hepatogastroentrology, Vol. 54, No. 79, 2007, pp. 2073-2077.
[15]	H. Yoshida, Y. Shratori, M. Kudo, et al., “Effect of Vitamin K2 on the Recurrence of Heptocellular Carcinoma,” Hepatology, Vol. 54, No. 2, 2011, pp. 532-540. Hdoi:10.1002/hep.24430
[16]	Liver Cancer Study Group of Japan, “The General Rules for the Clinical and Pathological Study of Primary Liver Cancer,” 4th Edition, Kanehara, Tokyo, 2000.
[17]	M. Kudo, H. Chung and Y. Osaki, “Prognostic Staging System for Hepatocellular Carcinoma (CLIP Score): Its Value and Limitations, and a Proposal for a New Staging System, the Japan Integrated Staging Score (JIS Score),” Journal of Gastroenterology, Vol. 38, No. 3, 2003, pp. 207-215. Hdoi:10.1007/s005350300038
[18]	A. Fujiwara, S. Mochida, A. Matsui, N. Nakayama, S. Nagoshi and G. Toda, “Intractable Liver Diseases Study Group Of Japan Fulminant Hepatitis and Late Onset Hepatic Failure in Japan,” Hepatology Research, Vol. 38, No. 7, 2008, pp. 646-657. Hdoi:10.1111/j.1872-034X.2008.00322.x
[19]	M. Kuwada and K. Katayama, “An Improved Method for Determination of γ-Carboxyglutamic Acid in Proteins, Bone and Urine,” Analytical Biochemistry, Vol. 131, No. 1, 1983, pp. 173-179. Hdoi:10.1016/0003-2697(83)90150-1
[20]	K. L. Berkner, “The Vitamin K-Dependent Carboxylase,” Annual Review of Nutrition, Vol. 25, 2005, pp. 127-149. Hdoi:10.1146/annurev.nutr.25.050304.092713
[21]	J. C. McCann, B. N. Ames and K. Vitamin, “An Example of Triage Theory: Is Micronutrient Inadequacy Linked to Disease of Aging?” The American Journal of Clinical Nutrition, Vol. 90, No. 4, 2009, pp. 889-907. Hdoi:10.3945/ajcn.2009.27930
[22]	K. Gotoh, S. Kato, S. Sumiya, S. Uehara, et al., “Urinary Levels of γ-Carboxyglutamic Acid and Its Clinical Significance,” Biological & Pharmaceutical Bulletin, Vol. 17, No. 1, 1994, pp. 142-145. Hdoi:10.1248/bpb.17.142
[23]	W. Sun, J. Fujimoto and T. Tamaya, “Coexpression of Gas6/ Axl in Human Ovarian Cancers,” Oncology, Vol. 66, No. 6, 2004, pp. 450-457. Hdoi:10.1159/000079499
[24]	D. Couchie, F. Lafdil, N. Martin-Garcia, Y. Laperche, E. S. Zafrani and P. Mavier “Expression and Role of Gas6 Protein and of Its Receptor Axl in Hepatic Regeneration from Oval Cells in the Rat,” Gastroenterology, Vol. 129, No. 5, 2005, pp. 1633-1642. Hdoi:10.1053/j.gastro.2005.08.004
[25]	F. Lafdil, M. N. Chobert, D. Couchie, et al., “Induction of Gas6 Protein in CCL4-Induced Rat Liver and Antiapoptotic Effect on Hepatic Stellate Cells,” Hepatology, Vol. 44, No. 1, 2006, pp. 228-239. Hdoi:10.1002/hep.21237
[26]	F. Lafdil, M. N. Chobert, V. Deveaux, et al., “Growth Arrest-Specific Protein 6 Deficiency Impairs Liver Tissue Repair after Acute Toxic Hepatitis in Mice,” Journal of Hepatology, Vol. 51, No. 1, 2009, pp. 55-66. Hdoi:10.1016/j.jhep.2009.02.030
[27]	M. Tjiwa, L. Bellido-Martin, Y. Lin, et al., “Gas6 Promotes Inflammation by Enhancing Interactions between Endothelial Cells, Platelets, and Leukocytes,” Blood, Vol. 111, No. 8, 2008, pp. 4096-4105. Hdoi:10.1182/blood-2007-05-089565
[28]	C. Ekman, A. Jonsen, G. Sturfelt, A. A. Bengtsson and B. Dahlb?ck, “Plasma Concentrations of Gas6 and sAxl Correlate with Disease Activity in Systemic Liphus Erythematosus and Its Soluble Tyrosine Kinase Receptor sAxl in Sepsis and Systemic Inflammatory Response Syndromes,” Critical Care, Vol. 14, No. 4, 2010, p. R158.
[29]	C. Ekman, D. F. Site, A. Gottsater, B. Lindblad and B. Dahlback, “Plasma Concentrations of Growth Arrest Specific Protein 6 and the Soluble Form of Its Tyrosine Kinase Receptor Axl as Markers of Large Abdominal Aortic Aneurysms,” Clinical Biochemistry, Vol. 43, No. 1-2, 2010, pp. 110-114. Hdoi:10.1016/j.clinbiochem.2009.07.025
[30]	C. Ekman, J. Stenhoff and B. Dahlback, “Gas6 Is Complexed to Souble Tyrosine Kinase Receptor Axl in Human Blood,” Journal of Thrombosis and Haemostasis, Vol. 8, No. 4, 2010, pp. 838-844.
[31]	A. Verma, S. L. Wamer, H. Vankayalapati, D. J. Bearss and S. Shrma, “Targeting Axl and Mer Kinases in Cancer,” Molecular Cancer Therapeutics, Vol. 10, No. 10, 2011, pp. 1763-1773. Hdoi:10.1158/1535-7163.MCT-11-0116
[32]	L. Loges, T. Schmidt, M. Tjwa, et al., “Malignant Cells Fuel Tumor Growth by Educating Infilutrating Leukocytes to Produce the Mitogen Gas6,” Blood, Vol. 115, No. 11, 2010, pp. 2264-2273. doi:10.1182/blood-2009-06-228684
[33]	A. Sica, “Macrophages Gives Gas6 to Cancer,” Blood, Vol. 115, No. 11, 2010, pp. 2122-2123. Hdoi:10.1182/blood-2009-12-255869
[34]	S. Uehara, K. Gotoh, H. Handa, H. Tomita and M. Senshuu, “Distribution of the Heterogeneity of Des-γ-Carboxyprothrombin in Patients with Hepatocellular Carcinoma,” Journal of Gastroenterology and Hepatology, Vol. 20, No. 10, 2005, pp. 1545-1552. Hdoi:10.1111/j.1440-1746.2005.03899.x
[35]	J. H. Foley and E. M. Conway, “Gas6 Gains Entry into the Coagulation Cascade,” Blood, Vol. 121, No. 4, 2013, pp. 570-571. Hdoi:10.1182/blood-2012-11-468678
[36]	L. Licuna, C. Bárcena, L. Bellido-Martin, et al., “Growth Arrest-Specific Protein 6 Is Hepatoprotective against Ischemia/Reperfusion Injury,” Hepatology, Vol. 52, No. 4, 2010, pp. 1371-1379.